Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) have been assigned a consensus recommendation of “Reduce” from the twelve ratings firms that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.20.
Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, October 15th. Wall Street Zen raised shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 14th.
Read Our Latest Report on FULC
Institutional Trading of Fulcrum Therapeutics
Fulcrum Therapeutics Price Performance
Shares of FULC stock opened at $3.71 on Friday. Fulcrum Therapeutics has a 1-year low of $2.83 and a 1-year high of $15.74. The firm has a fifty day moving average of $3.73 and a two-hundred day moving average of $5.41.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, research analysts forecast that Fulcrum Therapeutics will post -0.67 EPS for the current fiscal year.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.
Further Reading
- Five stocks we like better than Fulcrum Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
